Connect with us

Health

Emyria to seek approval for trial evaluating MDMA to treat PTSD – Stockhead

Nine years after a potentially groundbreaking Australian clinical trial evaluating the use of the psychoactive drug molly to treat post-traumatic stress disorder…

Published

on

Article feature image

Link copied toclipboard
Nine years after a potentially groundbreaking Australian clinical trial evaluating the use of the psychoactive drug molly to treat post-traumatic stress disorder was rejected on ethics grounds, an ASX-listed drug development company is taking another crack at it.
Emyria (ASX:EMD) announced this morning that in partnership with Mind Medicine Australia it would seek approval for a major clinical trial testing the use of MDMA to alleviate treatment-resistant PTSD.
Emyria managing…

Click here to view the original article.

Continue Reading
Advertisement

You might also like ...

Article feature image
Why Is COVID-19 So Hard To Treat? – Eurasia Review
Article feature image
Mucormycosis: The ‘black fungus’ maiming Covid patients in India – Yahoo News Australia